MicroRNA-Based Liquid Biopsy for Cervical Cancer Diagnostics and Treatment Monitoring
Author Information
Author(s): Kepsha Maria A., Timofeeva Angelika V., Chernyshev Vasiliy S., Silachev Denis N., Mezhevitinova Elena A., Sukhikh Gennadiy T.
Primary Institution: National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov, Ministry of Healthcare of the Russian Federation, Moscow
Hypothesis
Liquid biopsy using microRNAs can improve the diagnosis and monitoring of cervical cancer.
Conclusion
MicroRNAs in liquid biopsies show promise as non-invasive biomarkers for diagnosing and monitoring cervical cancer.
Supporting Evidence
- Liquid biopsy can analyze cancer-derived products in biofluids like blood.
- MicroRNAs are stable in extracellular vesicles and can serve as biomarkers.
- Studies show that circulating tumor cells correlate with treatment response.
- Persistent HPV DNA in blood is linked to worse outcomes in cervical cancer.
- Liquid biopsy allows for real-time monitoring of tumor progression.
Takeaway
Doctors can use tiny bits of RNA from blood to help find and track cervical cancer without needing to do surgery.
Methodology
This review discusses the potential of liquid biopsy techniques, particularly focusing on microRNAs, for cervical cancer diagnosis and monitoring.
Limitations
The review highlights the need for larger studies and standardized protocols for liquid biopsy techniques.
Participant Demographics
The study included patients with cervical cancer and healthy controls, with a focus on various demographics.
Statistical Information
P-Value
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website